why choose us

First received: August 10, 2023

Clinical Trial: A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: SARS-CoV-2 Infection

Study Type: INTERVENTIONAL


Official Title: A PHASE 2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED VACCINE CANDIDATES FOR SARS-CoV-2 NEW VARIANTS IN HEALTHY INDIVIDUALS

Brief Summary: The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.Substudy A:This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5)given as a single 30 µg dose,in people who are 12 years of age and older,who previously received at least 3 doses of a US-authorized mRNA COVID-19 vaccine, with the most recent dose being an Omicron…

Read more